Skip to content
Evigrade
ModerateDirect thrombin inhibitor×Other opioids

Updated · Methodology

Mechanism

Dabigatran is a direct thrombin inhibitor (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.1). In the RE-LY study, selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and noradrenaline reuptake inhibitors (SNRIs) increased the bleeding risk in all treatment groups. The dabigatran SmPC lists them among the factors that may increase bleeding risk and among the drugs that significantly increase the risk of major bleeding (EMA, sections 4.4 and 4.5). Tramadol is an opioid that, according to its US label, also weakly inhibits the reuptake of serotonin and noradrenaline (tramadol label, US Food and Drug Administration, FDA, sections 5.7 and 12.1). The documents do not address the combination of dabigatran and tramadol directly. The tramadol documents discuss bleeding only in connection with warfarin and other coumarins (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The documents also say nothing about either drug changing the levels of the other. Cytochrome P450 enzymes do not metabolise dabigatran, it has no effect on them in vitro, and it is eliminated mainly by the kidneys. Its pharmacokinetic restrictions concern inhibitors and inducers of the transporter P-glycoprotein (P-gp), and tramadol is not listed among them. CYP2D6 and CYP3A4 metabolise tramadol itself (EMA, sections 4.5 and 5.2; dabigatran FDA label, section 12.3; AEMPS, section 5.2).

Symptoms

The documents describe no symptoms linked to this combination. The main risk of dabigatran is bleeding. In clinical studies, bleeding was the most frequent adverse effect. It occurred in about 16.6% of patients with atrial fibrillation on long-term treatment and in 14.4% of adults treated for deep vein thrombosis or pulmonary embolism. Nosebleeds and gastrointestinal, skin and genitourinary bleeding are common. Major or severe bleeding was infrequent in clinical studies, but it can occur at any site and cause disability, be life-threatening or even fatal (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.8; dabigatran label, US Food and Drug Administration, FDA, section 5.2). The most frequent adverse effects of tramadol are nausea and dizziness, seen in more than 10% of patients. Headache, drowsiness, constipation, dry mouth, vomiting and sweating are common (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.8).

Management

The documents do not address this combination directly. The dabigatran SmPC lists selective serotonin and noradrenaline reuptake inhibitors (SNRIs) among the drugs that significantly increase the risk of major bleeding. With such drugs, the benefit and risk are weighed carefully, and dabigatran is prescribed only if the benefit outweighs the bleeding risk (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.4). Tramadol, according to its US label, weakly inhibits the reuptake of serotonin and noradrenaline (tramadol label, US Food and Drug Administration, FDA, section 5.7). The documents do not classify tramadol as a selective SNRI, so this strict dabigatran rule does not apply to it directly. The bleeding risk of the combination is still taken into account with the same caution. Throughout treatment, patients are watched closely for signs of bleeding or anaemia, especially when several risk factors are combined (EMA, section 4.4). In adults at increased risk of bleeding, the daily dabigatran dose (300 or 220 mg) is chosen on an individual assessment of thromboembolic and bleeding risk (EMA, section 4.2). An unexplained fall in haemoglobin, haematocrit or blood pressure calls for a search for a bleeding site. If severe bleeding occurs, dabigatran is stopped and the cause is investigated (EMA, section 4.4). Any signs or symptoms of blood loss are evaluated promptly (dabigatran FDA label, section 5.2). The pharmacokinetic restrictions of dabigatran concern inhibitors and inducers of the transporter P-glycoprotein (P-gp), and tramadol is not listed among them (EMA, section 4.5).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dabigatran

Other interactions with Tramadol